Lupus & antiphospholipid syndrome
Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
Authors' conclusion
ADA to rituximab were common and persisted over the 36-month period of this study. They associated with earlier drug elimination, an increased rate of relapse and demonstrated neutralizing capacity in vitro.
Study context
- Population
- Patients with SLE undergoing treatment with rituximab114 serum samples
- Participants
- 35 patients
- Exposure
- Anti-drug antibodies (ADA)-positive vs ADA-negative samples; persistent ADA positivity
- Outcome
- ADA persistence over time
- Follow-up
- 36 months
Methodological detailslongitudinal follow-up over 36 months, in vitro neutralization assay
- Longitudinal follow-up over 36 months
- In vitro neutralization assay
Main finding
As reported in the abstract
ADA persistence over the study period
ADA persisted over the 36-month study period
64.3%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Median circulating drug level until six months post rituximab infusionADA-positive vs ADA-negative | P = 0.0018 |
- Median circulating drug level until six months post rituximab infusion: significantly lower median drug level in ADA-positive samples
Disease activity and relapse with persistent ADA positivity
- Significant early improvement in disease activity followed by increased rates of relapse
Neutralizing capacity of ADA (in vitro, CDC assay)
- In vitro analysis confirmed the neutralizing capacity of ADA to rituximab
- Sub-cohort of positive samples (n = 38)
Original publication
Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Rheumatology (Oxford). Published 12 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →